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Abstract
Primary non-neuroendocrine tumours of the pituitary gland and sella are rare lesions often challenging to diagnose. We describe two
cases of clinically aggressive primary glomus tumour of the pituitary gland. The lesions occurred in a 63-year-old male and a 30-year-
old female who presented with headache, blurred vision and hypopituitarism. Neuroimaging demonstrated large sellar and suprasellar
tumours invading the surrounding structures. Histologically, the lesions were characterised by angiocentric sheets and nests of atypical
cells that expressed vimentin, smooth muscle actin and CD34. Perivascular deposition of collagen IV was also a feature. Case 2
expressed synaptophysin. INI-1 (SMARCB1) expression was preserved. Both lesions were mitotically active and demonstrated a Ki-
67 labelling index of 30%.Next-generation sequencing performed in case 1 showed nomutations in the reading frame of 37 commonly
mutated oncogenes, including BRAF andKRAS. Four pituitary glomus tumours have previously been reported, none of which showed
features of malignant glomus tumour. Similar to our two patients, three previous examples displayed aggressive behaviour.
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Introduction
Primary non-neuroendocrine tumours of the pituitary
gland and sellar region are rare and are often challeng-
ing to diagnose preoperatively and at pathological examina-
tion. If craniopharyngiomas and meningiomas are excluded,
the remaining 1% of sellar non-neuroendocrine neoplasms
includes the group of TTF-1 expressing tumours of the poste-
rior pituitary, neuronal and paraneuronal, germ cell,
haemopoietic, melanocytic, sellar salivary gland-like tumours,
the spectrum of mesenchymal neoplasms including
chordoma, and bone and cartilage tumours, sellar atypical
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teratoid rhabdoid tumour (ATRT), perivascular epithelial cell
neoplasm (PEComa) and glomus tumour (GT) [1–4].
Glomus tumour is a perivascular neoplasm that occurs
more commonly in the distal extremities and more often in-
volving the nail bed where glomus bodies are present. Glomus
tumours have also been documented in visceral organs such as
the lung, stomach, pancreas, liver, gastrointestinal and genito-
urinary tract [5, 6]. The pituitary gland is an uncommon site
for GT [7–10] where it probably derives from the thick tunica
media of hypophyseal portal vessels that are similar to glo-
mera of other sites and function as sphincter to regulate blood
flow [7, 11, 12]. Histologically, GTs resemble the normal
glomus bodies; glomangioma and glomangiomyoma repre-
sent morphological variants. Malignant GT (mGT) and
GT with uncertain malignant potential (GT-UMP) have
rarely been documented, predominantly in deep-seated
locations [6, 13].
We describe two patients with primary pituitary GT pre-
senting as large, invasive sellar and suprasellar lesions, one
with a fluctuating clinical behaviour due to tumour apoplexy




A 63-year-old male sought clinical attention in 2008 for
gynaecomastia without galactorrhoea. Hormonal tests re-
vealed normal prolactin, growth hormone deficiency and
hypogonadotropic hypogonadism, for which he was com-
menced on replacement therapy. Magnetic resonance imaging
(MRI) at that time documented an expanded sella and a bulky
pituitary gland but no tumour was observed. He presented
again in August 2018 with worsening intermittent headaches
and blurred vision. During that admission, he was diagnosed
with adrenal insufficiency and hypothyroidism. Replacement
therapy with hydrocortisone and levothyroxine was therefore
administered. His headaches gradually deteriorated and devel-
oped blurred vision. Visual fields were full with no evidence
of ophthalmoplegia. Investigations demonstrated worsening
of anterior hypopituitarism and additional adrenal insufficien-
cy. An MRI demonstrated a sellar lesion with suprasellar ex-
tension, left deviation of the stalk and slight optic chiasm
displacement without compression. The patient was referred
for pituitary surgery but the preoperative MRI showed spon-
taneous volumetric reduction with features consistent with
apoplexy (Fig. 1a). Headaches and visual disturbances re-
solved completely. Surgery was therefore deferred. In
June 2019, he returned with severe headaches and diplopia.
On examination, he had right sixth cranial nerve palsy. A new
MRI showed considerable enlargement of the lesion with
suprasellar extension, mild compression of the optic chiasm
and extension into the right cavernous sinus. There was also
an increased solid enhancing component and a small area of
central necrosis (Fig. 1b). The assessment of the hormonal
axis at his local hospital revealed hypopituitarism. A whole-
body CT scan was unremarkable.
The patient underwent endoscopic transsphenoidal sur-
gery. Intraoperatively the tumour appeared firm and rubbery
with a central area of relatively avascular, soft tissue consistent
with necrosis. The sellar floor was eroded; the tumour was
attached to the right side of the sphenoid septum. A residuum
was left in the right cavernous sinus. Headache and diplopia
resolved. He presented again 6 weeks later with diplopia and
deteriorating visual acuity. An MRI showed a regrowth of the
sellar and suprasellar components causing optic chiasm dis-
placement. Further surgery was felt inappropriate and he was
referred for adjuvant radiotherapy, which was completed in
November 2019. A follow-up MRI documented shrinkage of
the lesion following radiotherapy. He was re-admitted in
May 2020 with complete third nerve palsy and sudden visual
failure. An MRI demonstrated tumour progression with fur-
ther invasion of the cavernous sinuses and involvement of the
anterior cranial fossa (Fig. 1c). Further surgery and radiother-
apy were considered unfeasible given the extent of the tumour
and the patient has been referred for chemotherapy.
Patient 2
A 30-year-old female presented with a 10-month history of
progressive bilateral visual deterioration and amenorrhoea.
She initially refused an endocrinological assessment and a
brain MRI. She later sought clinical attention for a week his-
tory of severe headache and vomiting, suggesting acute in-
creased intracranial pressure or apoplexy. Clinical examina-
tion showed complete bilateral blindness with optic disc atro-
phy. Oculomotor movements were preserved. A brain MRI
showed a solid cyst, heterogeneously enhancing, intra- and
suprasellar lesion with pituitary fossa enlargement, optic chi-
asm compression, third ventricle extension and bilateral cav-
ernous sinus invasion. Oedema of the frontal lobes was also
present (Figure 2a, b, c). Hormonal tests documented hypopi-
tuitarism and hyponatraemia. She was given hydrocortisone
and levothyroxine and low sodium was corrected with hydric
restriction.
The patient underwent an endoscopic endonasal
transsphenoidal approach. Intraoperatively, the tumour was
firm and difficult to remove. A subtotal resection was accom-
plished with decompression of the optic chiasm. In the post-
operative course, she developed meningitis from Candida
Albicans, with secondary hydrocephalus that required an ex-
ternal ventricular drainage and then a ventriculoatrial shunt.
She remained hypopituitary on replacement therapy. She re-
fused gamma knife treatment and decided for transcranial
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surgery in another centre. Surgery was complicated by a
suprasellar haematoma, subarachnoid haemorrhage and
stroke. She developed aphasia, right-sided hemiparesis and
left-sided crural paresis and died 6 months after the second
operation.
Methods
The specimens were formalin fixed and embedded in paraffin.
Five-micron thick sections were stained with haematoxylin-
eosin (H&E). Immunohistochemistry was performed on a
BenchMark ULTRA Slide Staining System (Roche
Diagnostics, Indianapolis, IN, USA) using the primary anti-
bodies directed against synaptophysin (Novocastra, monoclo-
nal 27G12; dilution 1:500), FSH (Cell Marque Darmstadt
Germany, monoclonal 83/122A8; dilution 1:2000), LH (Cell
Marque, monoclonal 3LH5B6Y; dilution 1:100), TSH (Cell
Marque, monoclonal 5404; dilution 1:50), PRL (Biogenex,
monoclonal BGX031A; dilution 1:50), ACTH (Dako
Agilent, monoclonal, clone 02A3; dilution 1:1000), GH
(Cell Marque, monoclonal 54/92A2; dilution 1:50),
Fig. 2 (Patient 2) MR imaging at presentation including (A) coronal T2,
(B) post-contrast coronal T1 and (C) post-contrast sagittal T1 sequences
documents a large heterogeneous mass lesion with heterogeneously en-
hancing solid and cystic components and intra-tumoural haemorrhage
(A&B). The mass expands the sella and invades into the cavernous
sinuses bilaterally. There is marked suprasellar extension and compres-
sion of the optic chiasm. The tumour bulges into the anterior aspect of the
third ventricle (C) with secondary oedema and high T2 signal in the right
frontal lobe (A)
Fig. 1 (Patient 1) Preoperative coronal post-contrast T1 MRI documents
spontaneous resolution of the sellar lesion with a residual largely sellar
cystic lesion causing deviation of the pituitary stalk to the left. There is
minimal bulging into the suprasellar cistern but no compromise on the
optic chiasm (A). Coronal post-contrast T1 imaging after 4 months shows
interval deterioration in appearances with a recurrent solid enhancing
sellar mass invading the right cavernous sinus. There is also worsening
extension into the suprasellar cistern with displacement of the optic chi-
asm superiorly (B). Post-contrast coronal MRI after surgery and radio-
therapy shows a recurrent solid enhancing sellar mass invading the cav-
ernous sinuses bilaterally and with suprasellar extension (C)
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steroidogenic factor 1 (Abcam Cambridge UK, monoclonal
EPR19744; dilution 1:150), PIT1 (Novus Biologicals
Abingdon Oxon UK, polyclonal; dilution 1:100), TPIT
(Atlas Antibodies, Stockholm Sweden; monoclonal CL6251;
dilution 1:300), pancytokeratin (Novocastra Newcastle UK;
cocktail monoclonal AE1 andAE3; dilution 1:50), cytokeratin
7 (Dako Agilent Stockport UK, monoclonal OV-TL 12/3,
dilution 1:50), cytokeratin 8 (Becton Dickinson San Jose
CA, monoclonal CAM5.2; dilution 1:50), TTF-1 (Dako
Agilent, 8G7G3/1; dilution 1:100), vimentin (Dako Agilent,
monoclonal SRL-33; dilution 1:200), smooth muscle actin
(Dako Agilent, monoclonal M0851; dilution 1:500), desmin
(Dako Agilent, monoclonal M0760; dilution 1:100),
myogenin (Dako Agilent, monoclonal M3559; dilution
1:500), CD21 (Dako Agilent, monoclonal M0784l; dilution
1:100), CD23 (Leica Biosystems, Milton Keynes UK, mono-
clonal NCL-L-CD23-1B12; dilution 1:50), CD31 (Dako
Agilent, monoclonal M0823; dilution 1:30), CD34 (Dako
Agilent, monoclonal M7165; dilution 1:50), ERG (Roche
RTU; pre-diluted), Collagen IV (Roche RTU; pre-diluted),
STAT6 (Sigma Aldrich, Gillingham UK, rabbit polyclonal,
SAB4300331; dilution 1:100), GFAP (Dako Agilent, mono-
clonal 6F2; dilution 1:1000), S-100 protein (Dako Agilent;
polyclonal; dilution 1:1000), p63 (Biocare, Pacheco CA,
monoclonal 4A4; dilution 1:100), HMB45 (Dako Agilent,
monoclonal M0634; dilution 1:50), PAX8 (Proteintech, poly-
clonal; dilution 1:250), alpha-fetoprotein (Dako Agilent, rab-
bit polyclonal, dilution 1:500), INI-1 (Cell Marque, monoclo-
nal MRQ27; dilution 1:500), BRAFV600E (Ventana ,VE1
clone; pre-diluted), CD68 (Dako Agilent, clone KP1; dilution
1:200) and TFE3 (Roche RTU, polyclonal, pre-diluted).
The Ki-67 (Dako Agilent; monoclonal MIB-1, dilution
1:100) proliferative index was evaluated by counting the num-
ber of positive cells in at least 500 tumour cells in hotspot
areas on camera-captured printed images.
Next-generation sequencing
Themost representative tumour area of case 1 was circled on a
reference H&E-stained section. Five serial 10-micron thick
sections were cut from formalin-fixed and paraffin-
embedded tissue for DNA extraction. Genomic DNA was
isolated from the selected tissue area using the cobas® DNA
Sample Preparation Kit (Roche Diagnostics Ltd Burgess Hill
UK). Sequence analysis was carried out following PCR en-
richment using a QIAseq Targeted DNA custom panel
(Qiagen, Germantown, MD, USA) and Illumina next-
generation sequencing (Illumina, San Diego CA, USA). The
panel included AKT1, ALK, AR, ATRX, B2M, BRAF,
CDKN2A, CTNNB1, DDR2, EGFR, ERBB2, FGFR3,
GNA11, GNAQ, GNAS, H3F3A, H3F3B, HIST1H3B,
HIST1H3C, HIST2H3C, HRAS, IDH1, IDH2, KIT, KRAS,
MAP2K1, MET, NRAS, PDGFRA, PIK3CA, PTEN, RET,
STK11, TERT, TP53 and VHL. The whole coding sequence
was not targeted. Mutation and variant calling by custom bio-
informatics analysis pipeline validated to detect SNVs and
small insertion/deletion mutations (< 40 bp) to 5% mutant
allele frequency. Alterations were categorised following the
American College of Medical Genetics guidelines and
Association for Molecular Pathology tiering.
Pathological findings
Both tumours showed moderate to high cellularity and
consisted of nests, sheets and ill-defined lobules in a dense
network of thin-walled vessels. Neoplastic cells were of small
to medium size and showed neat borders, densely eosinophilic
cytoplasm and irregular nucleus with fine chromatin and in-
conspicuous nucleolus. Several nuclei contained optically
clear inclusions. Cytoplasmic vacuoles were present in some
cells. Tumour cells often seemed to arise from or form them-
selves vessel walls (Figures 3a, 3b, 4a). No adeno- or neuro-
hypophysis was present in the specimens. Mitotic count was
up to 10 × 10 HPFs at × 400 magnification in case 1 and 2 ×
10 HPFs in case 2. Lesion 1 also showed focal necrosis and
haemorrhagic changes.
Neoplastic cells of both lesions expressed vimentin, SMA,
which was focal in case 1 and diffuse in case 2 and CD34 that
was focal in case 2; the immunoreaction for collagen IV
showed pericellular pattern. Synaptophysin was only
expressed in case 2. Scattered tumour cells in case 1 demon-
strated membranous EMA immunoreactivity. SMARCB1/
INI1 was normally expressed, CD68 highlighted macro-
phages and CD31 highlighted the dense vascular network.
All other immunostains were negative. The Ki-67 labelling
index was 30% in both tumours (Figures 3c, d, e, f, g and h
and 4b, c, d, e and f).
The NGS panel did not identify any mutations in the read-
ing frame of the 37 genes tested.
Discussion
We have documented two primary GTs of the pituitary pre-
senting as a large, invasive sellar and suprasellar masses. Both
patients underwent repeated surgeries.
Given the site of the two lesions, the diagnosis of GT in our
patients was challenging. Angiocentric sheets of tumour cells
expressing vimentin, SMA and CD34 were important clues to
reach the diagnosis of GT [5, 6]. The vascular network was
not prominent enough to suggest glomangioma, no smooth
muscle cells were identified to suggest glomangiomyoma
and no bizarre cells were present for the symplastic variant
of GT. Similar to our cases, GTs typically express vimentin
and SMA [6], while CD34 has only been reported in some
cases [9, 14]. Pericellular deposition of reticulin fibres and
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collagen type IV is also a common feature of GT and it high-
lights pericellular basal membranes. Neoplastic cells of case 2
expressed synaptophysin similar to the sellar GT documented
by Tsang and colleagues and to visceral examples [10]. Our
cases met the criteria of mGT [13] and showed malignant
features from onset rather than during progression including
high mitotic rate and high Ki-67 labelling index. Although the
relevance of tumour size and extension is not established in
pituitary GTs, the two lesions reported here were larger than
2 cm and locally invasive. It is accepted that designation of
GT-UMP and mGT may not necessarily imply an aggressive
clinical course; nevertheless mGTs recur frequently and have
metastatic potential requiring a long-term follow-up and adju-
vant treatment [13].
Fig. 3 (Patient 1) The lesion is
composed of densely cellular
sheets of tumour cells that form
thin-walled vessels (A, HE, × 20).
Neoplastic cells have epithelioid
features and display eosinophilic
cytoplasm and hyperchromatic
nucleus; atypical mitoses are also
present (arrowhead) (B, HE, ×
40); vimentin is diffusely
expressed (C, immunoperoxidase
× 20); smooth muscle actin is fo-
cally expressed in tumour cells
(D, immunoperoxidase, ×40);
there is pericellular deposition of
collagen IV (E,
immunoperoxidase, × 40); tu-
mour cells expressed CD34
(F, immunoperoxidase × 20) and
retain INI-1 nuclear expression
(G, immunoperoxidase × 20).
About 30% of tumour cells ex-
press Ki-67 (H,
immunoperoxidase, × 20)
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No mutations in the open reading frame of commonly mu-
tated oncogenes, including BRAF and KRAS, were identified
in our patient 1. Strong nuclear INI-1 expression in both le-
sions indicated that mutations in SMARCB1 were unlikely to
have occurred. The genetic features of GT, GT-UMP and
mGT are not fully understood [15]. BRAFV600E and KRAS
mutations were documented in superficially located GTs in-
cluding GT-UMP and mGTs [16]. Dabek and colleagues
found a stop gain mutation C > T in exon 6 and the frameshift
truncation c.1148delC in exon 9 in SMARCB1 [17]; unlike our
cases, immunohistochemistry confirmed the loss of INI-1 ex-
pression. GTs have been described in neurofibromatosis type
1 [18, 19], but our patients had no stigmata and family history
of the condition. No multiple GTs were identified to suggest
an inherited condition such as mutations in the glomulin gene
[20]. Rearrangements and novel fusion genes MIR143-
NOTCH2 and MIR143-NOTCH1 were found in malignant
GTs [21] but they were not tested in our cases.
Given the location of our cases, we considered a broad
differential diagnosis. Synaptophysin expression seen in our
case 2 and in one published example [10] could havemisled to
an erroneous diagnosis of aggressive immunonegative pitui-
tary neuroendocrine tumour. The absence of lineage-restricted
pituitary transcription factors along with vimentin, SMA,
CD34 and collagen IV expression was not in keeping with a
tumour that originated from adenohypophyseal cells.
Paraganglioma, sellar melanocytic tumour, sellar ATRT,
atypical meningioma, myoepithelial carcinoma, malignant
solitary fibrous tumour, PEComa and epithelioid
leiomyosarcoma were also considered in the differential diag-
nosis but light microscopic features and immunoprofile of the
present lesions excluded these possibilities. Finally, we con-
sidered a mesenchymal neoplasm with a pericytic phenotype
driven by fusions of GLI1 with the partner genes ACTB1,
MALAT1 or PTCH1 [22]. Histologically, tumours with GLI1
aberrations show nests, cords and reticular structures of mono-
morphic round to epithelioid cells in a dense capillary network
that can mimic GT. Unlike our GT, GLI1-fused tumours ex-
press S100 protein and are negative for SMA. A metastasis
from amalignant GTwas excluded clinically because no other
lesion was found outside the sella.
Primary pituitary GT with features of glomangioma was
first documented by Asa and colleagues in 1984 [7]. Since
their report, other three cases have been published [8–10].
The essential clinical and pathological features of these four
and our cases are summarised in Table 1. The previously
documented pituitary GTs occurred in three adults aged 42,
47, 72 years [7–9] and an 8-year-old child [10]. Two were
female [8, 10]. The tumours caused headache, visual impair-
ment and intermittent diplopia. Two patients had
panhypopituitarism, one at onset [10] and one after the second
operation [10]. All tumours were sellar with suprasellar exten-
sion; cavernous sinus invasion was recorded in two cases [8,
9]. Similar to our patients, tumour removal was sub-total.
Adjuvant radiotherapy was administered to three patients [7,
8, 10]. Three patients had multiple local tumour recurrences
Fig. 4 (Patient 2) The tumour is composed of sheets of atypical cells in a
network of thin-walled vessels (A, × 20 –HE); neoplastic cells show diffuse
expression of vimentin (B, immunoperoxidase × 20) and smooth muscle
actin (C, immunoperoxidase × 20), focal CD34 (D, immunoperoxidase ×
40) and diffuse synaptophysin (E, immunoperoxidase × 20); increase in Ki-
67 is focal with areas showing up to 30% of positive tumour cells (F,
immunoperoxidase × 10)
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between 3 and 26 years from onset [7–10]. One patient died of
tumour progression 12 years after the diagnosis [8].
Histologically, two lesions were described as glomangioma
[7, 9] although these had predominant spindle cell morpholo-
gy [9] leading to consider spindle cell oncocytoma,
pituicytoma and meningioma in the differential diagnosis. A
delicate fibre network surrounding individual tumour cells is a
hallmark of pituitary GTs. SMA was described in all cases
without any mention to focal expression as it was seen in
our case 1. CD34 was tested in three cases and was negative
in tumour cells. Synaptophysin was investigated in one lesion
where it was found to be diffusely positive, in the absence of
chromogranin and CD56 expression [10]. Electron microsco-
py was performed in three cases [7–9] and revealed medium-
sized tumour cells featuring microvilli, pinocytotic vesicles,
large mitochondria, myofibrils with focal condensation into
dense bodies and basal lamina surrounding individual cells.
Mitoses were described in two primary tumours without pro-
viding an accurate count [7, 10]. One case demonstrated in-
creased cellular atypia and increased mitoses and Ki-67 at
recurrence in keeping with a diagnosis of GT-UMP [10].
However, none of the previously documented cases presented
with microscopic features of mGT in the primary lesion.
BRAFV600E status was tested by immunohistochemistry in
one instance [10]; otherwise, no genetic testing or immuno-
stain for INI-1 was performed.
Conclusion
In conclusion, we documented two primary GTs of the pitui-
tary gland displaying aggressive histological features at onset.
Glomus tumour should be considered in the differential diag-
nosis of rare primary non-neuroendocrine tumours of the pi-
tuitary gland and sellar region as they present as invasive
lesions that are difficult to remove surgically, have the tenden-
cy to recur locally, causing severe morbidity to patients, and
require adjuvant treatment, predominantly radiotherapy as the
evidence of efficacy of chemotherapy protocols remains very
limited. Pituitary GTs can be diagnostically challenging, par-
ticularly when they show severe cellular atypia and high pro-
liferation. As recommended by Tsang and colleagues [10], it
is essential that the appropriate panel of immunostains that
includes SMA and CD34 is requested to reach the diagnosis
and inform on outcome.
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